Benitec Biopharma Inc.
NASDAQ: BNTC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jerel A. Banks
- Employees
- 16
- Headquarters
- Hayward, United States
- IPO year
- 2014
- Market cap
- $357.7M
- Website
- https://benitec.com
Loading BNTC…
Loading profile data…Frequently asked questions about BNTC
What does Benitec Biopharma Inc. (BNTC) do?
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at...
Where does BNTC trade?
Benitec Biopharma Inc. (BNTC) trades on the NASDAQ Capital Market.
What sector is BNTC in?
Benitec Biopharma Inc. (BNTC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Benitec Biopharma Inc.?
Jerel A. Banks is the chief executive officer of Benitec Biopharma Inc. (BNTC).
Where is Benitec Biopharma Inc. headquartered?
Benitec Biopharma Inc. is headquartered in United States.
Does BNTC pay a dividend?
Benitec Biopharma Inc. (BNTC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BNTC go public?
Benitec Biopharma Inc. (BNTC) completed its initial public offering in 2014.